Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
USD 36.0
(-7.98%)
USD 36.0
(-7.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -408.16 Million USD | 28.43% |
| 2022 | -570.27 Million USD | -166.74% |
| 2021 | -213.79 Million USD | -80.16% |
| 2020 | -118.66 Million USD | 77.56% |
| 2019 | -528.8 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -319.77 Million USD | -78.14% |
| 2024 Q1 | -179.5 Million USD | -24.0% |
| 2023 Q2 | -90.34 Million USD | -28.16% |
| 2023 FY | -408.16 Million USD | 28.43% |
| 2023 Q1 | -70.49 Million USD | 64.95% |
| 2023 Q3 | -102.57 Million USD | -13.53% |
| 2023 Q4 | -144.75 Million USD | -41.12% |
| 2022 Q1 | -97.03 Million USD | -87.01% |
| 2022 FY | -570.27 Million USD | -166.74% |
| 2022 Q4 | -201.1 Million USD | -192.08% |
| 2022 Q3 | -68.85 Million USD | 66.13% |
| 2022 Q2 | -203.28 Million USD | -109.51% |
| 2021 Q4 | -51.88 Million USD | 4.56% |
| 2021 Q1 | -264.96 Million USD | 0.0% |
| 2021 Q2 | -210.61 Million USD | 20.51% |
| 2021 Q3 | -54.36 Million USD | 74.19% |
| 2021 FY | -213.79 Million USD | -80.16% |
| 2020 Q2 | -180.93 Million USD | -4.62% |
| 2020 FY | -118.66 Million USD | 77.56% |
| 2020 Q3 | -195.18 Million USD | -7.88% |
| 2020 Q1 | -172.93 Million USD | -15.86% |
| 2019 Q1 | -62.3 Million USD | 0.0% |
| 2019 FY | -528.8 Million USD | 0.0% |
| 2019 Q4 | -149.26 Million USD | -40.59% |
| 2019 Q3 | -106.16 Million USD | 49.7% |
| 2019 Q2 | -211.07 Million USD | -238.77% |
| 2018 Q3 | -61.44 Million USD | -56.46% |
| 2018 Q1 | -85.46 Million USD | -185.37% |
| 2018 Q2 | -39.26 Million USD | 54.05% |
| 2017 Q2 | -38.44 Million USD | -104.98% |
| 2017 Q3 | -42.91 Million USD | -11.64% |
| 2017 Q4 | 100.1 Million USD | 333.27% |
| 2017 Q1 | -18.75 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ADC Therapeutics SA | -240.05 Million USD | -70.032% |
| Alto Neuroscience, Inc. | -36.3 Million USD | -1024.275% |
| Annovis Bio, Inc. | -56.2 Million USD | -626.222% |
| Ginkgo Bioworks Holdings, Inc. | -892.86 Million USD | 54.286% |
| Nuvation Bio Inc. | -75.8 Million USD | -438.466% |
| Nuvation Bio Inc. | -75.8 Million USD | -438.466% |
| Arcus Biosciences, Inc. | -307 Million USD | -32.954% |
| Theriva Biologics, Inc. | -18.34 Million USD | -2124.47% |
| Zymeworks Inc. | -118.67 Million USD | -243.941% |